Pfizer Investment Enterprises Pte Ltd
Full Lot
Price as of 03 Oct 2026, 1:27am
Odd Lot
Price as of 03 Oct 2026, 1:27am
Ask Yield to Worst
Bid Yield to Worst
Ask Yield to Maturity
Bid Yield to Maturity
Bond Issuer
Pfizer Investment Enterprises Pte Ltd
Guarantor
Pfizer Inc
Announcement Date
16 May 2023
Issue Date
19 May 2023
Maturity Date
19 May 2053
Years to Maturity / Next Call
26.642 / 26.146
Modified Duration
12.868 @ 02 Oct 2026
Issue / Reoffer Price
99.851
Issue / Reoffer Yield
5.310
Coupon Type
Fixed
Annual Coupon Rate
5.300
Coupon Frequency
Semi Annually
Seniority
Senior Unsecured
Reference Rate
-
ISIN
US716973AG71
CUSIP
716973AG7
Bond Currency
USD
Total Issue Size
6,000,000,000
Min. Investment Quantity (Nominal)
USD 2,000
Incremental Quantity (Nominal)
USD 1,000
Bond Type
Corporate
Bond Sector
Health Care
Bond Sub Sector
Pharmaceuticals
Issuer Credit Rating (S&P/ Fitch)
***/ N.R
Bond Credit Rating (S&P/ Fitch)
***/ W.R
Shariah Compliant
No
Exchange Listed
Others
Par Call Date: November 19, 2052
(1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming such notes matured on the applicable Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus (i) 15 basis points in the case of the 2026 notes, (ii) 15 basis points in the case of the 2028 notes, (iii) 20 basis points in the case of the 2030 notes, (iv) 20 basis points in the case of the 2033 notes, (v) 20 basis points in the case of the 2043 notes, (vi) 25 basis points in the case of the 2053 notes and (vii) 25 basis points in the case of the 2063 notes less (b) interest accrued to, but excluding, the date of redemption, and
(2) 100% of the principal amount of such notes to be redeemed, plus, in either case, accrued and unpaid interest on the notes being redeemed to, but excluding, the redemption date.
If (i) the Merger is not consummated on or before the Special Mandatory Redemption End Date or (ii) the Issuer notifies the trustee under the indenture that Parent will not pursue consummation of the Merger, the Issuer will be required to redeem each series of the Notes, other than the 2033 Notes and the 2053 Notes, at a redemption price equal to 101% of the principal amount of such series of the Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. The Special Mandatory Redemption will not apply to the 2033 Notes and the 2053 Notes. In the event of a triggering of the Special Mandatory Redemption and following completion of the Special Mandatory Redemption, the Parent will assume the obligations of the Issuer under the 2033 Notes and the 2053 Notes and will become the successor issuer of the 2033 Notes and the 2053 Notes, the Issuer will no longer be an obligor under the 2033 Notes and the 2053 Notes and the Guarantee with respect to the 2033 Notes and the 2053 Notes will be released in full. The assumption of the 2033 Notes and the 2053 Notes by the Parent shall be treated as a Parent Assumption (as defined herein) for purposes of the indenture.
Cash Flow Information
